Patent ID: 8071299

Claim:
A method for identifying a multiple sclerosis (MS) human patient having an inferior response to a treatment of MS by administration of interferon-alpha (IFN-Î±) and/or interferon-beta (IFN-Î²) comprising: (a) determining in a sample from the human patient the presence of polymorphisms in AXL and MGC20255, wherein the polymorphism in AXL is at position 41782 of SEQ ID NO:1, and the polymorphism in MGC20255 is at position 130468 of SEQ ID NO:1; and (b) identifying the human patient as having an inferior response to a treatment of MS with administration of interferon-alpha (IFN-Î±) and/or interferon-beta (IFN-Î²) when the patient has either CT or TT in AXL at position 41782 of SEQ ID NO:1, and AA in MGC20255 at position 130468 of SEQ ID NO:1.